Global Non-Invasive Prenatal Testing Market is expected to grow at a healthy rate of 16% to reach $9 billion by 2026
Non-invasive prenatal testing (NIPT), is a method of determining the risk of whether the fetus of the mother will be born with certain genetic abnormalities. NIPT is a safe and highly effective way of screening for conditions such as Down syndrome, Edwards syndrome , Patau syndrome, monosomy X, and Turner syndrome . Currently, there is two types of NIPT methods that are commercially available, massive parallel sequencing (MPS) technology and the single-nucleotide polymorphism (SNP) based method. Rapid Shift towards Cell-Free DNA screening The Discovery of cell-free DNA (cfDNA)-based NIPT has created a rapid shift in the paradigm of aneuploidy screening during pregnancy. It’s a simple blood test that can be performed during pregnancy. Clinical validation studies suggest that NIPT is more accurate than combined first-trimester screening (CFTS), with very high sensitivity (99.3%) and specificity (99.9%) for trisomy 21(Down syndrome). NIPT is also safer than other invasive diagnostic...